Table 3 Comparison of the effect of hymecromone on pulmonary lesions in COVID-19 patients classified by different hospitalization

From: Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression

Hospital staya

CT change

Control group

Experimental group

P value*

X < 14

Improvement

10 (42%)

11 (100%)

Yes

Exacerbation

14 (58%)

0 (0%)

14 ≤ X ≤ 28

Improvement

30 (45%)

24 (86%)

P = 0.0002

Exacerbation

37 (55%)

4 (14%)

28 ≤ X ≤ 35

Improvement

2 (22%)

6 (86%)

P = 0.0406

Exacerbation

7 (78%)

1 (14%)

Total numbers

Improvement

42 (42%)

41 (89%)

P < 0.0001

Exacerbation

58 (58%)

5 (11%)

  1. aThe number of days was used to classify the hospital day
  2. *P value was calculated by Fisher’s exact test using GraphPad Prism
Back to article page